•
394
INTERVENCIÓN PERCUTÁNEA CORONARIA
15 A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator fer acute myocardial infarction. The Global
Use af Strategies ta Open Occluded Caronary Arteries in Acute Coronary Syndromes (GUSTO !lb) Angioplasty Substudy Investigators. N
Eng!J Med. 1997;336:1621-1628.
.
16 Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, Grinfeld L, Gibbons RJ, Ribeiro EE, DeWood MA, Ribichini F.
Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative revlew
[published correction appears in JAMA. 1998;279:1876]. JA MA. 1997;278:2093-2098.
17 Berger AK, Schulman KA, Gersh BJ, Pirzada S, Breall JA, lohnson AE, Every NR. Primary coronary angioplasty vs thrombolysis far the
management of acute myocardial infarction in elderly patients. JAMA. 1999; 282:341-348.
18 Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a
quantitative review of 23 randomised trials. Lancet 2003¡361:13-20.
19 Nallamothu BK, Bates ER. Percutaneous coronary intervention versus frbrinolytic therapy in acute myocardial infarction: is timing
(almost) everything? Am J cardiol. 2003;92:824-826.
20 Zij1stra F, Patel A, Janes M, Grines CL, Ellis S, Garcla E, Grinfeld L, Gibbons RJ, Ribeiro EE, Ribichini F, Granger C, Akhras F, Weaver
WD, Simes RJ. Clinical characteristics and outcome of patients with early L2 h), intermediate (2-4 h) and late (_ 4 h) presentation
treated by primary coronary angioplasty ar thrombolytic therapy far acute myocardial infarction. Eur Heart J. 2002;23:550 -557.
CLOPIDROGUEL
21 Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognonl G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute
coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494 -502.
22 Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland !,
Fax KA. Effects of pretreatment with clopidogrel and aspirin fallowed by long-term therapy in patients undergoing percutaneous
coronary intervention: the PCl-CURE study. Lancet 2001;358:527-533.
23 Yusuf S, Mehta SR, Zhao F, Gersh Bl, cammerford PJ, Blumenthal M, Budaj A, Wittlinger T, Fax KA. Early and late effects of
clopidogrel in patients with acute coronary syndromes. Oiwlation. 2003;107: 966-972.
24 Budaj A, Yusuf S, Mehta SR, Fax KA, Tognoni G, Zhao F, Chrolavicius S, Hunt D, Keltai M, Franzosi MG. Benefit of clopidogrel in
patients with acute coronary syndromes without ST-segment elevation in various risk groups. Cirr:ulation. 2002; 106: 1622-1626.
25 Peters RJ, Mehta SR, Fax KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford Pl, Valentin V, Yusuf S. Effects of aspirin dose
when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in
Unstable angina to preven! Recurren! Events (CURE) study. Circu/ation. 2003;108: 1682-1687 .
26 Fax KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh Bl, Yusuf S. Benefits and risks of the combination of clopidogrel and aspirin in
patients undergoing surgical r�scu1arization far non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to
prevent Recurren! ischemic Events (CURE) Trial. Circulation. 2004;110: 1202-1208.
27 CAPRIE Steering Committee. A randomised, blinded, tria! of clopidogrel versus aspirln ln patients at risk of ischaemic events
(CAPRJE). Lancet 1996;348:1329 -1339.
28 Steinhubl SR, Berger PB, Mann JT III, Fry ET, Delago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy
fallowing percutaneous coronary intervention: a randomized controlled trial. JA MA. 2002;268:2411-2420.